ReviewNeuroendocrinology2020
Diagnosis, Background, and Treatment of Hypothalamic Damage in Craniopharyngioma.
Review in Neuroendocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Hyperphagia in rare melanocortin-4 receptor pathway diseases: therapeutic options and assessing treatment response.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Factors associated with acquired hypothalamic obesity in children with hypothalamic tumors: a comparative single-center study.Endocrine · 2026Article
- Kisspeptin as a test of hypothalamic dysfunction in pubertal and reproductive disorders.Andrology · 2026Review
- Hyperphagia in craniopharyngioma- a real-world study from the international hypothalamic-pituitary brain tumors patient registry.Scientific reports · 2026Article
- Endocrine and metabolic consequences of childhood-onset craniopharyngioma during the transition age: A literature review by the TALENT study group.Reviews in endocrine & metabolic disorders · 2025Review
- Limitations of MRI in differentiating solid and cystic components of craniopharyngiomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Virtual Reality and Three-Dimensional Printing of Craniopharyngioma: A Case Report Proposing an Innovative Model of Pediatric Endocrine Care to Enhance Patient Engagement.Clinical case reports · 2025Article
- Editorial: Advances and challenges in adult-onset craniopharyngioma.Frontiers in endocrinology · 2025Article
- Endocrine sequelae after pediatric craniopharyngioma treatment: a single-center retrospective cohort study.Journal of pediatric endocrinology & metabolism : JPEM · 2024Article
- Comparison of central diabetes insipidus (antidiuretic hormone deficiency) and stalk effect in patients with adamantinomatous and papillary craniopharyngioma.Acta neurologica Belgica · 2024Article
- Integrated Microbiome and Metabolome Analysis Reveals Hypothalamic-Comorbidities Related Signatures in Craniopharyngioma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Article
- Review
- Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma.Endocrine oncology (Bristol, England) · 2024Article
- Treatment and outcome of the Dutch Childhood Craniopharyngioma Cohort study: First results after centralization of care.Neuro-oncology · 2023Article
- Shifting Strategies in the Treatment of Pediatric Craniopharyngioma.Current oncology reports · 2023Review
- Single-cell RNA sequencing highlights intratumor heterogeneity and intercellular network featured in adamantinomatous craniopharyngioma.Science advances · 2023Article
- Automated segmentation of craniopharyngioma on MR images using U-Net-based deep convolutional neural network.European radiology · 2023Article
- Treatment of hypothalamic obesity in people with hypothalamic injury: new drugs are on the horizon.Frontiers in endocrinology · 2023Review
- Deep-learning-based automatic segmentation and classification for craniopharyngiomas.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Craniopharyngiomas (CP) are rare brain tumors managed primarily with surgery and radiotherapy. There are 2 phenotypes of CP, i.e., one with a rather good outcome without hypothalamic damage and another with hypothalamic damage. With hypothalamic damage, progressive disease with recurrent operations and additional cranial radiotherapy often result in hypothalamic obesity, an affected psychosocial life, and cognitive dysfunction. The morbidity and mortality are increased for particularly cerebrovascular diseases. Preoperative hypothalamic involvement to predict hypothalamic damage is important for decision making for hypothalamus-sparing surgery. Also a postoperative hypothalamic damage evaluation with the use of hypothalamus volume measurement can predict hypothalamic obesity, which is important for early treatment options. The morbidity of CP includes cognitive dysfunction with attention deficits and impaired episodic memory and processing speed. Again patients with hypothalamic damage are more affected. Treatment options of hypothalamic obesity in the chronic phase are scarce and not convincingly successful. The most optimal situation is to try to hinder or stop the evolution of hypothalamic obesity. Prevention of hypothalamic damage is recommended, with special regard to hypothalamus-sparing therapeutic approaches that respect the integrity of essential nuclei located in both the medial and the posterior hypothalamic areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.